Understanding — How Cannabinoids Work
The Whole-Plant Principle: What Research Shows About Phytochemical Complexity
Isolated compounds and whole-plant preparations behave differently — what the research has established about why, and what remains an open question.
The history of botanical medicine is largely a history of working with whole plants. Macerations, decoctions, infusions, tinctures — the traditional preparation forms preserved across cultures and centuries all begin with the plant in something close to its complete form, and extract from it without first separating what is considered useful from what is considered unnecessary. Modern pharmaceutical chemistry moved in a different direction: isolate the active constituent, purify it, standardize it, study it alone. Both approaches have produced genuine benefits. What the research is beginning to clarify is that they are not interchangeable.
A Plant Produces More Than Its Most Famous Compound
Hemp produces cannabinoids as one category of phytochemical among several. In the same trichomes where CBG and CBD are synthesised, the plant also produces terpenes — volatile aromatic compounds that account for much of hemp's distinctive scent — and flavonoids, a class of polyphenolic compounds found across the plant kingdom with documented biological activities of their own. These are not byproducts or incidental passengers. They are the plant's phytochemical expression, shaped by genetics, growing conditions, soil, season, and harvest timing.
A preparation that works with the whole flower — alcohol maceration, oil infusion, cold-process extraction — preserves this full profile. A preparation that isolates a single cannabinoid, or that begins with a broad-spectrum extract from which most compounds have been removed, delivers something meaningfully different. The question that research is working to answer is whether that difference matters biologically, and in what specific ways.
The Dose-Response Question — Where the Most Relevant Evidence Sits
One of the more cited pieces of evidence in this area comes from a 2015 study by Blasco-Benito and colleagues examining tumour responses in mouse models. Comparing a CBD isolate to a whole-plant CBD-rich extract, the researchers found that the whole-plant extract produced a broader dose-response curve — it showed biological activity across a wider range of doses than the isolated CBD. This finding has been invoked frequently in hemp marketing as evidence of synergy. What it actually shows is more specific and more interesting than that general claim.
The practical implication of a broader dose-response curve — if the finding holds across contexts, which has not been established — is that a whole-plant preparation may be less sensitive to precise dosing than an isolate. This is a pharmacologically meaningful observation. It does not establish that whole-plant preparations are more effective than isolates at equivalent doses in human populations. It is a Tier 2 preclinical finding, in a specific model, with a specific outcome measure. It is worth knowing about. It is not the basis for confident clinical claims.
A separate line of evidence comes from observational data in human populations. Studies examining CBD use in different preparation forms — including one by MacCallum and Russo in 2018 reviewing clinical and preclinical findings — have found that patients in clinical settings often report that whole-plant preparations require lower doses than isolates to achieve comparable subjective effects. This is observational data without randomised controlled trial design, and the potential for placebo and expectation effects is significant. But the pattern is consistent enough across independent observations to take seriously as a hypothesis worth investigating formally.
What Specific Compounds Contribute
The most mechanistically coherent evidence for compound interaction in whole-plant hemp preparations involves beta-caryophyllene — a sesquiterpene present in hemp, black pepper, cloves, and other botanicals. Beta-caryophyllene was demonstrated by Gertsch and colleagues in 2008 to act as a direct agonist at CB2 receptors, making it the only terpene currently documented to engage the endocannabinoid system through a specific receptor mechanism. This is not a theoretical interaction — it is a documented pharmacological finding published in a peer-reviewed journal and replicated in subsequent work.
CB2 receptors are expressed primarily in immune tissue and play a role in inflammatory signalling. A whole-flower hemp preparation preserves beta-caryophyllene alongside CBG and CBD, meaning the preparation contains three compounds with documented CB2 activity — two cannabinoids and one terpene — acting through mechanisms that are distinct but at the same receptor target. Whether they interact additively, synergistically, or not at all in a human preparation context has not been formally studied. That they are all present and all have individual evidence at CB2 is a documented botanical fact.
Minor cannabinoids contribute a second layer of complexity. CBG, CBD, CBC, and CBN are the primary named cannabinoids in the research literature, but hemp produces dozens of minor cannabinoids in smaller quantities — CBGV, CBDV, CBCV, and others — that have their own preliminary evidence at various receptor systems. A whole-plant preparation contains this full minor cannabinoid profile alongside the primaries. An isolate contains none of it. A broad-spectrum extract may preserve some, depending on the processing method. The research on minor cannabinoids is early — Tier 3 for most — but their presence in a whole-plant preparation is not theoretical.
Flavonoids add a third layer. Hemp-specific flavonoids — particularly the cannflavins — have their own research profile, including documented COX enzyme inhibition in preclinical studies conducted as early as the 1980s. Cannflavin A and cannflavin B showed anti-inflammatory activity in cell models at concentrations that suggested meaningful potency. This research has seen renewed interest recently. It is early, it is primarily in vitro, and it does not establish clinical efficacy. But it does establish that the flavonoid fraction of a whole-plant preparation is not biologically inert.
What Preparation Method Actually Preserves
Terpenes are volatile — they evaporate readily with heat and are lost in extraction processes that use high temperatures or aggressive solvents. A slow alcohol maceration at room temperature, or a gentle oil infusion at controlled low heat, preserves terpenes that CO2 extraction or high-heat ethanol processes may significantly reduce. This is a documented difference in preparation chemistry, not a theoretical one. A certificate of analysis on a whole-flower alcohol tincture and a CO2 isolate preparation will show different terpene profiles, and the difference is attributable to preparation method.
Minor cannabinoids and flavonoids are similarly affected by processing. Refinement and distillation steps that are standard in producing broad-spectrum extracts reduce the minor cannabinoid profile substantially. A whole-flower preparation that never undergoes those steps retains the full minor cannabinoid and flavonoid profile as expressed in the plant at harvest.
This is the grounded case for whole-plant preparation — not a specific synergy claim that exceeds the evidence, but a documented difference in phytochemical composition between preparation methods. The compounds that are present in a whole-plant preparation and absent from a processed one have their own individual evidence bases. Their biological availability in a whole-plant preparation is not in question. What research continues to investigate is the nature and magnitude of their interactions.
Whole-plant preparations contain a measurably different phytochemical profile from isolates or broad-spectrum extracts — this is a documented fact of preparation chemistry, not a marketing claim. Beta-caryophyllene's CB2 agonism is the most thoroughly established specific terpene-receptor interaction in this context, representing Tier 2 evidence. The dose-response curve data from Blasco-Benito et al. (2015) is the most relevant preclinical evidence for preparation-type differences, but is a single mouse model study with a specific outcome measure — Tier 2 at best in this context. Observational clinical data suggesting lower effective doses with whole-plant preparations relative to isolates is consistent but not controlled — hypothesis-generating rather than conclusive.
What is not established: no adequately powered randomised controlled trial has directly compared the clinical outcomes of whole-plant hemp preparations against equivalent-dose isolates in human populations for any specific condition. The specific nature and magnitude of phytochemical interactions in whole-plant preparations remain active research questions. Preparation-type claims that assert superiority without qualification exceed the current evidence. The case for whole-plant preparation rests on documented phytochemical preservation and individual compound evidence — and that case is both honest and sufficient without requiring unestablished synergy claims.
References
- Blasco-Benito, S., Seijo-Vila, M., Caro-Villalobos, M., et al. (2018). Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochemical Pharmacology, 157, 285–293.
- Gertsch, J., Leonti, M., Raduner, S., et al. (2008). Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences, 105(26), 9099–9104.
- MacCallum, C.A., & Russo, E.B. (2018). Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine, 49, 12–19.
- Mechoulam, R., Ben-Shabat, S., Hanus, L., et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.
- Morales, P., Hurst, D.P., & Reggio, P.H. (2017). Molecular targets of the phytocannabinoids: A complex picture. Progress in the Chemistry of Organic Natural Products, 103, 103–131.
- Russo, E.B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
- Appendino, G., Gibbons, S., Giana, A., et al. (2008). Antibacterial cannabinoids from Cannabis sativa: A structure-activity study. Journal of Natural Products, 71(8), 1427–1430.
- Barrett, M.L., Gordon, D., & Evans, F.J. (1985). Isolation from Cannabis sativa L. of cannflavin — identification as 6-methoxyflavone and its presence in confiscated cannabis samples. Biochemical Pharmacology, 34(11), 2019–2024.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.